Skip to main content

Cardiologists' Perspectives on Race-Based Drug Labels and Prescribing Within the Context of Treating Heart Failure.

Publication ,  Journal Article
Callier, SL; Cunningham, BA; Powell, J; McDonald, MA; Royal, CDM
Published in: Health equity
January 2019

Purpose: Cardiologists are known to consider patients' race when treating heart failure, but their views on the benefits and harms of this practice are largely undocumented. We set out to explore cardiologists' perspectives on the benefits and harms of race-based drug labels and guidelines. Specifically, we focused on isosorbide dinitrate and hydralazine hydrochloride (sold in a patented form as BiDil), a combination of drugs recommended for the treatment of black patients receiving optimal medical therapy for symptomatic heart failure and reduced ejection fraction. Methods: We conducted 81 semistructured interviews at an American College of Cardiology Annual meeting to assess cardiologists' and cardiology fellows' attitudes toward the use of race in drug prescribing. Investigators reviewed and coded the interviews using inductive qualitative analysis techniques. Results: Many participants believed that race-based drug labels might help doctors prescribe effective medications to patients sooner. More than half of the participants expressed concerns, however, that considering race within the context of treating heart failure could potentially harm patients as well. Harms identified included the likelihood that patients who could benefit from a drug may not receive it because of their race; insufficient understanding about gene-drug-environment interactions; and simplistic applications of race in the clinic. Conclusions: Few participants expressed approval of using race in drug prescribing without recognizing the potential harms, yet most participants stated that they continue to consider race when prescribing isosorbide dinitrate and hydralazine hydrochloride. Within the context of treating heart failure, more open discussions about the benefits and harms of race-based drug labels and prescribing are needed to address cardiologists' concerns.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Health equity

DOI

EISSN

2473-1242

ISSN

2473-1242

Publication Date

January 2019

Volume

3

Issue

1

Start / End Page

246 / 253

Related Subject Headings

  • 4206 Public health
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Callier, S. L., Cunningham, B. A., Powell, J., McDonald, M. A., & Royal, C. D. M. (2019). Cardiologists' Perspectives on Race-Based Drug Labels and Prescribing Within the Context of Treating Heart Failure. Health Equity, 3(1), 246–253. https://doi.org/10.1089/heq.2018.0074
Callier, Shawneequa L., Brooke A. Cunningham, Jill Powell, Mary Anne McDonald, and Charmaine D. M. Royal. “Cardiologists' Perspectives on Race-Based Drug Labels and Prescribing Within the Context of Treating Heart Failure.Health Equity 3, no. 1 (January 2019): 246–53. https://doi.org/10.1089/heq.2018.0074.
Callier SL, Cunningham BA, Powell J, McDonald MA, Royal CDM. Cardiologists' Perspectives on Race-Based Drug Labels and Prescribing Within the Context of Treating Heart Failure. Health equity. 2019 Jan;3(1):246–53.
Callier, Shawneequa L., et al. “Cardiologists' Perspectives on Race-Based Drug Labels and Prescribing Within the Context of Treating Heart Failure.Health Equity, vol. 3, no. 1, Jan. 2019, pp. 246–53. Epmc, doi:10.1089/heq.2018.0074.
Callier SL, Cunningham BA, Powell J, McDonald MA, Royal CDM. Cardiologists' Perspectives on Race-Based Drug Labels and Prescribing Within the Context of Treating Heart Failure. Health equity. 2019 Jan;3(1):246–253.

Published In

Health equity

DOI

EISSN

2473-1242

ISSN

2473-1242

Publication Date

January 2019

Volume

3

Issue

1

Start / End Page

246 / 253

Related Subject Headings

  • 4206 Public health